Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-62,166
Closed -$54.3K 1984
2023
Q4
$54.3K Buy
62,166
+53
+0.1% +$37 ﹤0.01% 1981
2023
Q3
$46.8K Buy
62,113
+39,987
+181% +$30.4K ﹤0.01% 1883
2023
Q2
$16.2K Buy
22,126
+30
+0.1% +$28 ﹤0.01% 1869
2023
Q1
$16.7K Buy
22,096
+145
+0.7% +$135 ﹤0.01% 1847
2022
Q4
$21.1K Sell
21,951
-131
-0.6% -$185 ﹤0.01% 1786
2022
Q3
$48K Buy
22,082
+235
+1% +$810 ﹤0.01% 1690
2022
Q2
$76K Buy
21,847
+5,814
+36% +$21.7K ﹤0.01% 1656
2022
Q1
$81K Sell
16,033
-170
-1% -$861 ﹤0.01% 1621
2021
Q4
$102K Buy
16,203
+5,078
+46% +$34.7K ﹤0.01% 1640
2021
Q3
$88K Buy
+11,125
New +$91.6K ﹤0.01% 1562

Other funds holding VXRT

AE Wealth Management's VXRT Position: Q1 2024 in Review

AE Wealth Management sold out of Vaxart (VXRT) in Q1 2024, closing a stake of 62,166 shares — an estimated $54.3K sold.

AE Wealth Management first reported a position in VXRT in Q3 2021 and held it in 10 quarters. The position peaked at $102K in Q4 2021. 106 funds tracked by Wall St. Rank hold VXRT as of Q1 2024.

  • AE Wealth Management reported no remaining Vaxart position as of Q1 2024 after selling out during the quarter.
  • AE Wealth Management sold 62,166 Vaxart shares in Q1 2024, an estimated $54.3K.
  • AE Wealth Management first reported a position in Vaxart in Q3 2021 and held it in 10 quarters.
  • AE Wealth Management's Vaxart position peaked at $102K in Q4 2021.
  • 106 funds tracked by Wall St. Rank held Vaxart as of Q1 2024.

Based on AE Wealth Management's 13F filing for Q1 2024, filed 15 May 2024.